Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program
Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds
08-Aug-2012 -
Horizon Discovery Ltd announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a number ...
oncology